PIPELINE

The MedXCell Group is a clinical-stage company with products spanning discovery, development, pre-clinical validation and formal clinical studies utilizing innovative cellular therapies.  Products within the company’s pipeline represent two major platforms, natural killer (NK) cells for oncology applications, and mesenchymal stromal cells (MSC) for osteoarthritis.

PROGRAM

INDICATION

DISCOVERY

PRE-CLINICAL

PHASE I/II

PIVOTAL

MXNK-101

CD20+ Cancers (B-NHL)

0%
POC on the platform

MXNK-103

AML

0%

MXNK-289

Solid Tumor

0%

MXNK-xxx

Undisclosed

0%

ADIPOA

Knee Osteoarthritis

0%

B-NHL: B-Cell Non-Hodgkin Lymphoma

AML: Acute Myeloid Leukemia